Sirtuin 6 ameliorates bleomycin-induced pulmonary fibrosis via activation of lipid catabolism
© 2023 Wiley Periodicals LLC..
Pulmonary fibrosis is a chronic and serious interstitial lung disease with little effective therapies currently. Our incomplete understanding of its pathogenesis remains obstacles in therapeutic developments. Sirtuin 6 (SIRT6) has been shown to mitigate multiple organic fibrosis. However, the involvement of SIRT6-mediated metabolic regulation in pulmonary fibrosis remains unclear. Here, we demonstrated that SIRT6 was predominantly expressed in alveolar epithelial cells in human lung tissues by using a single-cell sequencing database. We showed that SIRT6 protected against bleomycin-induced injury of alveolar epithelial cells in vitro and pulmonary fibrosis of mice in vivo. High-throughput sequencing revealed enriched lipid catabolism in Sirt6 overexpressed lung tissues. Mechanismly, SIRT6 ameliorates bleomycin-induced ectopic lipotoxicity by enhancing lipid degradation, thereby increasing the energy supply and reducing the levels of lipid peroxides. Furthermore, we found that peroxisome proliferator-activated receptor α (PPARα) was essential for SIRT6-mediated lipid catabolism, anti-inflammatory responses, and antifibrotic signaling. Our data suggest that targeting SIRT6-PPARα-mediated lipid catabolism could be a potential therapeutic strategy for diseases complicated with pulmonary fibrosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:239 |
|---|---|
| Enthalten in: |
Journal of cellular physiology - 239(2024), 3 vom: 01. März, Seite e31027 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
He, Jiangping [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
11056-06-7 |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jcp.31027 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356033228 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356033228 | ||
| 003 | DE-627 | ||
| 005 | 20240316232506.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jcp.31027 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1332.xml |
| 035 | |a (DE-627)NLM356033228 | ||
| 035 | |a (NLM)37099691 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a He, Jiangping |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sirtuin 6 ameliorates bleomycin-induced pulmonary fibrosis via activation of lipid catabolism |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley Periodicals LLC. | ||
| 520 | |a Pulmonary fibrosis is a chronic and serious interstitial lung disease with little effective therapies currently. Our incomplete understanding of its pathogenesis remains obstacles in therapeutic developments. Sirtuin 6 (SIRT6) has been shown to mitigate multiple organic fibrosis. However, the involvement of SIRT6-mediated metabolic regulation in pulmonary fibrosis remains unclear. Here, we demonstrated that SIRT6 was predominantly expressed in alveolar epithelial cells in human lung tissues by using a single-cell sequencing database. We showed that SIRT6 protected against bleomycin-induced injury of alveolar epithelial cells in vitro and pulmonary fibrosis of mice in vivo. High-throughput sequencing revealed enriched lipid catabolism in Sirt6 overexpressed lung tissues. Mechanismly, SIRT6 ameliorates bleomycin-induced ectopic lipotoxicity by enhancing lipid degradation, thereby increasing the energy supply and reducing the levels of lipid peroxides. Furthermore, we found that peroxisome proliferator-activated receptor α (PPARα) was essential for SIRT6-mediated lipid catabolism, anti-inflammatory responses, and antifibrotic signaling. Our data suggest that targeting SIRT6-PPARα-mediated lipid catabolism could be a potential therapeutic strategy for diseases complicated with pulmonary fibrosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Sirtuin 6 | |
| 650 | 4 | |a bleomycin | |
| 650 | 4 | |a lipid catabolism | |
| 650 | 4 | |a peroxisome proliferator-activated receptor α | |
| 650 | 4 | |a pulmonary fibrosis | |
| 650 | 7 | |a Bleomycin |2 NLM | |
| 650 | 7 | |a 11056-06-7 |2 NLM | |
| 650 | 7 | |a PPAR alpha |2 NLM | |
| 650 | 7 | |a SIRT6 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.5.1.- |2 NLM | |
| 650 | 7 | |a Sirtuins |2 NLM | |
| 650 | 7 | |a EC 3.5.1.- |2 NLM | |
| 700 | 1 | |a Yu, Cong |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yunlong |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jiao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yanzi |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Jianmin |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Quan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cellular physiology |d 1965 |g 239(2024), 3 vom: 01. März, Seite e31027 |w (DE-627)NLM000005304 |x 1097-4652 |7 nnns |
| 773 | 1 | 8 | |g volume:239 |g year:2024 |g number:3 |g day:01 |g month:03 |g pages:e31027 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jcp.31027 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 239 |j 2024 |e 3 |b 01 |c 03 |h e31027 | ||